COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
AssigneeAlnylam Pharmaceuticals, Inc.
InventorsNader Najafian, Jae Kim, Mustafa Varoglu, Gabriel Robbie
Life of this patent
Estimating the term…
Abstract
The invention relates to methods for treating subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria, using iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and anti-C5 antibodies, e.g., eculizumab.
Claims29
A method for treating a subject having paroxysmal nocturnal hemoglobinuria (PNH), the method selected from the group consisting of
- a) a method, comprising administering to an eculizumab naïve subject a 200-400 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every week;
- and
- administering to the subject a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
- wherein the dsRNA agent comprises a sense strand and an antisense strand, and
- wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
- wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively;
- Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively;
- dT is a deoxy-thymine nucleotide;
- and s is a phosphorothioate linkage, thereby treating the subject;
- b) a method, comprising administering to an eculizumab naïve subject a 200-400 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every month;
- and
- administering to the subject a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
- wherein the dsRNA agent comprises a sense strand and an antisense strand, and
- wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
- wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively;
- Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively;
- dT is a deoxy-thymine nucleotide;
- and s is a phosphorothioate linkage, thereby treating the subject;
- c) a method, comprising administering to an eculizumab naïve subject a 200 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every week for 10-15 weeks, followed by a 400 mg fixed dose of the dsRNA agent once every week;
- and
- administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
- wherein the dsRNA agent comprises a sense strand and an antisense strand, and
- wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
- wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively;
- Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively;
- dT is a deoxy-thymine nucleotide;
- and s is a phosphorothioate linkage, thereby treating the subject;
- d) a method, comprising administering to an eculizumab naïve subject a 200 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every month for 2 to 4 months;
- and
- administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
- wherein the dsRNA agent comprises a sense strand and an antisense strand, and
- wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
- wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively;
- Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively;
- dT is a deoxy-thymine nucleotide;
- and s is a phosphorothioate linkage, thereby treating the subject;
- e) a method, comprising administering to an eculizumab naïve subject a 400 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every week;
- and
- administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
- wherein the dsRNA agent comprises a sense strand and an antisense strand, and
- wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
- wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively;
- Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively;
- dT is a deoxy-thymine nucleotide;
- and s is a phosphorothioate linkage, thereby treating the subject;
- and
- f) a method, comprising administering to an eculizumab naïve subject a 400 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every month;
- and
- administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
- wherein the dsRNA agent comprises a sense strand and an antisense strand, and
- wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
- wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively;
- Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively;
- dT is a deoxy-thymine nucleotide;
- and s is a phosphorothioate linkage, thereby treating the subject.
-6. (canceled)
A method for treating a subject having paroxysmal nocturnal hemoglobinuria (PNH), the method selected from the group consisting of
- a) a method, comprising administering to a subject previously treated with eculizumab, a 400 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every week;
- and
- administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
- wherein the dsRNA agent comprises a sense strand and an antisense strand, and
- wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
- wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively;
- Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively;
- dT is a deoxy-thymine nucleotide;
- and s is a phosphorothioate linkage, thereby treating the subject;
- b) a method, comprising administering to a subject previously treated with eculizumab, a 400 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every month;
- and
- administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
- wherein the dsRNA agent comprises a sense strand and an antisense strand, and
- wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
- wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively;
- Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively;
- dT is a deoxy-thymine nucleotide;
- and s is a phosphorothioate linkage, thereby treating the subject;
- c) a method, comprising administering to a subject previously treated with eculizumab, a 400 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every week for 2-8 weeks;
- and
- administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
- wherein the dsRNA agent comprises a sense strand and an antisense strand, and
- wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
- wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively;
- Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively;
- dT is a deoxy-thymine nucleotide;
- and s is a phosphorothioate linkage, thereby treating the subject;
- d) a method, comprising administering to a subject previously treated with eculizumab, a 400 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every month for 1-2 months;
- and
- administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
- wherein the dsRNA agent comprises a sense strand and an antisense strand, and
- wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
- wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively;
- Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively;
- dT is a deoxy-thymine nucleotide;
- and s is a phosphorothioate linkage, thereby treating the subject;
- e) a method, comprising administering to a subject previously treated with eculizumab, a 200 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every week;
- and
- administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
- wherein the dsRNA agent comprises a sense strand and an antisense strand, and
- wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
- wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively;
- Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively;
- dT is a deoxy-thymine nucleotide;
- and s is a phosphorothioate linkage, thereby treating the subject;
- f) a method, comprising administering to a subject previously treated with eculizumab, a 200 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every month;
- and
- administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
- wherein the dsRNA agent comprises a sense strand and an antisense strand, and
- wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
- wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively;
- Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively;
- dT is a deoxy-thymine nucleotide;
- and s is a phosphorothioate linkage, thereby treating the subject;
- g) a method comprising administering to a subject that has not responded to treatment with eculizumab, a 200 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every week;
- and
- administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
- wherein the dsRNA agent comprises a sense strand and an antisense strand, and
- wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
- wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively;
- Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively;
- dT is a deoxy-thymine nucleotide;
- and s is a phosphorothioate linkage, thereby treating the subject;
- h) a method comprising administering to a subject that has not responded to treatment with eculizumab, a 200 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every month;
- and
- administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
- wherein the dsRNA agent comprises a sense strand and an antisense strand, and
- wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
- wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively;
- Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively;
- dT is a deoxy-thymine nucleotide;
- and s is a phosphorothioate linkage, thereby treating the subject;
- i) a method, comprising administering to a subject that has not responded to treatment with eculizumab, a 400 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every week;
- and
- administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
- wherein the dsRNA agent comprises a sense strand and an antisense strand, and
- wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
- wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively;
- Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively;
- dT is a deoxy-thymine nucleotide;
- and s is a phosphorothioate linkage, thereby treating the subject;
- and
- j) a method comprising administering to a subject that has not responded to treatment with eculizumab, a 400 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every month;
- and
- administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
- wherein the dsRNA agent comprises a sense strand and an antisense strand, and
- wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
- wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively;
- Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively;
- dT is a deoxy-thymine nucleotide;
- and s is a phosphorothioate linkage, thereby treating the subject.
-16. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-30. (canceled)
-41. (canceled)
-49. (canceled)
Dependencies are inferred from the claim text.